Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 5/20 | 0.35 |
| ▸ | ERAP2 | Q6P179 | 4/20 | 0.35 |
| ▸ | ACP3 | P15309 | 3/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23884969 | 0.79 | PLA2G1B (0.48) | KMT2AHTT | |
| SCHEMBL13541384 | 0.79 | LOXL2 (0.45) | CA2CA4CA5AENPP1 | |
| SCHEMBL1377592 | 0.78 | KMT2A (0.55) | CA2MEN1KMT2AHTTANPEP | |
| SCHEMBL5667423 | 0.75 | CA2 (0.52) | CA2CA4CA5AENPP1MEN1 | |
| SCHEMBL1378120 | 0.75 | CA12 (0.50) | — | |
| SCHEMBL13538579 | 0.75 | ACP3 (0.41) | CA2CA4CA5AENPP1MEN1 | |
| SCHEMBL2171752 | 0.74 | CA2 (0.71) | CA2CA4CA5AMEN1KMT2A | |
| SCHEMBL3362601 | 0.73 | CA2 (0.50) | CA2CA4CA5AENPP1 | |
| SCHEMBL3809678 | 0.72 | TPSAB1 (0.44) | CA2MEN1KMT2AHTT | |
| SCHEMBL3809675 | 0.72 | LMNA (0.45) | ENPP1MEN1KMT2AAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109071577-A | thyroid hormone receptor agonists and uses thereof | 症变治疗公司 | 2018-12-21 | — | — | CN | disclosed |
| CN-102718759-A | Heterocyclic CETP inhibitors | BRISTOL MYERS SQUIBB CO | 2012-10-10 | — | — | CN | disclosed |
| CN-101024736-B | Aluminium oxide-containing dispersion, preparation containing the dispersion and melamine resin and solidified product prepared by the preparation | DEGUSSA | 2011-03-30 | — | — | CN | disclosed |
| CN-101842356-A | Polymorphs of (3- (((4-tert-butylbenzyl) - (pyridine-3-sulfonyl) -amino) -methyl) -phenoxy) -acetic acid sodium salt or hydrate thereof and process for producing the same | PFIZER PROD INC | 2010-09-22 | — | — | CN | disclosed |
| CN-101663262-A | N- (3-benzyl) -2, 2- (diphenyl) -propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases | BRISTOL MYERS SQUIBB CO | 2010-03-03 | — | — | CN | disclosed |
| CN-101528699-A | Heterocyclic cetp inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2009-09-09 | — | — | CN | disclosed |
| CN-101437804-A | Dibenzyl amine compounds and derivatives | PFIZER PROD INC (US) | 2009-05-20 | — | — | CN | disclosed |
| CN-101437803-A | Dibenzyl amine derivatives as CETP inhibitors | PFIZER PROD INC (US) | 2009-05-20 | — | — | CN | disclosed |
| CN-101356161-A | Heterocyclic CETP inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2009-01-28 | — | — | CN | disclosed |
| CN-100439337-C | Phenyl substituted piperidine compounds for use as PPAR activators | PFIZER PROD INC (US) | 2008-12-03 | — | — | CN | disclosed |
| CN-101024736-A | Aluminium oxide-containing dispersion, preparation containing the dispersion and melamine resin and solidified product prepared by the preparation | DEGUSSA (DE) | 2007-08-29 | — | — | CN | disclosed |
| CN-1942448-A | Novel imidazoles | WARNER LAMBERT CO (US) | 2007-04-04 | — | — | CN | disclosed |
| CN-1852719-A | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a bisphosphonate | PFIZER (US) | 2006-10-25 | — | — | CN | disclosed |
| CN-1795177-A | 1, 2, 4-substituted 1, 2, 3, 4-tetrahydro-and 1, 2 dihydro-quinolines and 1, 2, 3, 4-tetrahydro-quinoxaline derivatives as CETP inhibitors for the treatment of atherosclerosis and obesity | PFIZER PROD INC (US) | 2006-06-28 | — | — | CN | disclosed |
| CN-1717389-A | Phenyl substituted piperidine compounds for use as PPAR activators | PFIZER PROD INC (US) | 2006-01-04 | — | — | CN | disclosed |
| CN-1476429-A | EP4 receptor selective agonists in treatment of osteoporosis | �Ʒ� | 2004-02-18 | — | — | CN | disclosed |
| CN-1241176-A | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | PFIZER (US) | 2000-01-12 | — | — | CN | disclosed |
| CN-1157565-A | Method for treatment of osteoporosis using bone active phosphonates and parathyroid hormone | PROCTER & GAMBLE (US) | 1997-08-20 | — | — | CN | disclosed |
| CN-1157566-A | Phosphonates and parathyroid hormone for osteoporosis | PROCTER & GAMBLE (US) | 1997-08-20 | — | — | CN | disclosed |
| CN-1147762-A | Oral compositions | PROCTER & GAMBLE (US) | 1997-04-16 | — | — | CN | disclosed |